Evidence Level
Probiotics are live microorganisms that confer health benefits when consumed in adequate amounts. The evidence supporting their efficacy is extensive but varies by strain and condition. Ford et al. (2018) conducted a landmark meta-analysis of 53 randomized controlled trials (RCTs) in irritable bowel syndrome (IBS), demonstrating significant symptom improvement with probiotics, particularly multi-strain combinations. Wu et al. (2024) further supported this finding through a systematic review and network meta-analysis of 54 RCTs involving 6528 participants, confirming that probiotics are effective for managing IBS.
Beyond digestive health, Hao et al. (2015) highlighted the immune-modulating effects of probiotics in a Cochrane systematic review, showing they reduce the risk of acute upper respiratory tract infections. The gut-brain axis has emerged as a frontier, with Wallace & Milev (2017) reviewing evidence for "psychobiotics," specific strains that influence mood and cognition through neural, immune, and endocrine pathways.
Recent studies have also explored probiotics' role in other conditions. Vaz et al. (2024) found that probiotics reduced infantile colic crying by an average of 51 minutes daily in a meta-analysis of 15 RCTs. Soleimanpour et al. (2024) demonstrated significant improvement in behavioral symptoms among individuals with autism spectrum disorder, based on a systematic review and meta-analysis of 8 studies.
However, probiotic use is not without nuance. Suez et al. (2018) reported that post-antibiotic probiotic use can delay native microbiome recovery in some individuals, emphasizing the importance of strain selection and personalized approaches.
Overall, probiotics offer diverse health benefits across multiple conditions, though their efficacy depends on strain specificity and individual circumstances.